Halozyme Therapeutics Inc. (Nasdaq: HALO) licensed its Enhanze technology to Bristol-Myers Squibb (NYSE: BMY) for $105 million upfront and Roche for $30 million upfront. Shares of Halozyme soared $2.80 to close at $15.98 while Bristol-Myers stock added 22 cents to close at $62.70.
Halozyme licenses Enhanze for $135 million
September 14, 2017 at 17:50 PM EDT